For innovation companies, highly differentiated and technologically advanced biobetters offer the greatest potential to mitigate the risks associated with the introduction of biosimilars, as they can be approved before the patent expires and have blockbuster potential.
Related Articles Read More >

BBy creates first condensed-to-powder breast milk, announces seed funding

Thermo Fisher Scientific expands steriles manufacturing and research capabilities in Asia-Pacific region

RotaChrom rCPC platform adheres to CGMP guidelines for pharmaceuticals
